CAMS-Oxford Institute Principal Investigator, Ricardo Fernandes, has been awarded a competitive grant from Cancer Research UK to study anti-tumour T cell responses.
New research published in Nature Communications suggests that the currently recommended five-day course of molnupiravir, an antiviral treatment, may not be long enough to treat COVID-19.
A new study led by the Big Data Institute at NDM has found persistent COVID-19 infections are surprisingly common, with around one to three in every 100 infections lasting a month or longer.
Recent findings by the Global Research on Antimicrobial Resistance Project at NDM's Centre for Tropical Medicine and Global Health revealed the resistance patterns for a priority pathogen--also known as typhoid fever--with high mortality and morbidity in resource-constrained settings.
The phase III trial data results of the R21/Matrix-M vaccine, developed by the Jenner Institute and the Serum Institute of India have confirmed high efficacy and supported regulatory approvals and licensure in several African countries.
This World Cancer Day, we heard from four Group Leaders at the MRC Weatherall Institute of Molecular Medicine about their work and how their groups are helping in the fight against cancer.
The largest multiparameter immunoprofiling study in cancer to date has suggested an underappreciated role of a subset of immune cells in determining the risk of bowel cancer relapse after surgery.
A new hepatitis B study reveals how viruses adapt to low-oxygen environments, such as those found deep within the liver, opening up possible new therapeutic targets for liver pathogens. NDM researchers have identified hypoxia-inducible factors (HIFs) playing an important role in the regulation of editing of viral RNAs in low oxygen conditions.
Researchers at the Jenner Institute, the Oxford Vaccine Group and the Pandemic Sciences Institute hosted the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.
Research led by scientists at the Universities of Oxford, Cambridge, Copenhagen, Bristol and California (Berkeley) reveals the evolutionary origins of multiple sclerosis (MS). This new insight into the genetic architecture of this disease changes scientists\u2019 view of its causes and has implications for its treatment, as well as paving the way for further investigations into other diseases.
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of \u00a37,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential. The awards will fund research into vaccines against: Chikungunya and mayaro virus, Marburg virus, Plague (Yersinia pestis), Q Fever (Coxiella burneti) and Sudan Ebolavirus.
![\"\"](\"https://www.immunology.ox.ac.uk/news/ricardo-fernandes-awarded-a-cancer-research-uk-immunology-project-award/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n